Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Plexxikon CEO: Expect Business As Usual, After Whopping $805 Million Daiichi Sankyo Buyout

This article was originally published in PharmAsia News

Executive Summary

Bidding by multiple companies and strong data for a late-stage, targeted melanoma drug helped drive Daiichi Sankyo Company Limited's eye-popping $805 million acquisition of privately-held Plexxikon Inc.

You may also be interested in...

Daiichi Sankyo Teams With National Cancer Center For Japanese Drug Discovery

Under the agreement, Japan’s National Cancer Center will provide the company with clinical research results and drug targets.

Daiichi Sankyo New R&D Head Puts Emphasis On Faster Decision-making

Daiichi Sankyo has four large Phase III milestones in the next two years, followed by prioritization for early stage programs

Cash-rich Japanese Pharma Now In A Position To Snatch Up Compounds, But Many Face Decision-making Bottlenecks - BIO Japan

YOKOHAMA, Japan - The impact of the strong yen appreciation has been severe for Japanese companies, contributing to sales dips as foreign markets balked at the rising prices for Japanese products. But the strong yen can also be a positive for Japanese consumers, including Japan Pharma shopping around for early-stage biotech compounds

Related Content

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts